New Drug Pomalidomide
Researchers involved in an international trial have reported that pomalidomide is active for the treatment of anemia associated with myelofibrosis. The details of this study appeared in an early online publication in the Journal of Clinical Oncology on August 3, 2009.
Pomalidomide is an oral analog of thalidomide with significant immunomodulatory effects. It stops the growth of blood vessels, stimulates the immune system, and may directly kill cancer cells. Pomalidomide is also an angiogenesis inhibitor. A Phase I study showed a complete remission rate of 17% in patients with relapsed or refractory myeloma with daily pomalidomide. The main side effects were deep vein thrombosis, which occurred early and late. A Phase II study used an alternate-day regimen of pomalidomide in an attempt to decrease thrombotic side effects. The alternate-day schedule appeared to eliminate thrombotic complications. The complete response rate in patients with relapsed myeloma was 10%, and a greater than 50% reduction in paraprotein was achieved in half the patients.
At ASH 2008 daily pomalidomide and low-dose dexamethasone was evaluated in 37 patients with relapsed or refractory myeloma. The overall response rate was 62%, while 24% had a very good partial response.
It appears that pomalidomide can be added to Revlimid as an active derivative of thalidomide with possibly fewer side effects.
Pomalidomide is an oral analog of thalidomide with significant immunomodulatory effects. It stops the growth of blood vessels, stimulates the immune system, and may directly kill cancer cells. Pomalidomide is also an angiogenesis inhibitor. A Phase I study showed a complete remission rate of 17% in patients with relapsed or refractory myeloma with daily pomalidomide. The main side effects were deep vein thrombosis, which occurred early and late. A Phase II study used an alternate-day regimen of pomalidomide in an attempt to decrease thrombotic side effects. The alternate-day schedule appeared to eliminate thrombotic complications. The complete response rate in patients with relapsed myeloma was 10%, and a greater than 50% reduction in paraprotein was achieved in half the patients.
At ASH 2008 daily pomalidomide and low-dose dexamethasone was evaluated in 37 patients with relapsed or refractory myeloma. The overall response rate was 62%, while 24% had a very good partial response.
It appears that pomalidomide can be added to Revlimid as an active derivative of thalidomide with possibly fewer side effects.
posted by gwg at 10:27 AM
0 Comments:
Post a Comment
<< Home